NCT02437591View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 13, 2015

Primary Completion Date

May 12, 2016

Study Completion Date

October 24, 2016

Conditions

Inflammatory Bowel Disease (IBD)Clostridium Difficile Infection (CDI)

Interventions

DRUG

fidaxomicin

oral

Trial Locations (12)

8036

Site AT43001, Graz

11527

Site GR30004, Athens

35128

Site IT39003, Padua

75012

Site FR33001, Paris

92110

Site FR33002, Clichy

119435

Site RU70003, Moscow

129110

Site RU70002, Moscow

196247

Site RU70001, Saint Petersburg

Unknown

Site IT39001, Roma

02-507

Site PL48002, Warsaw

02-781

Site PL48003, Warsaw

E11 1NR

Site GB44002, London

All Listed Sponsors

lead

Astellas Pharma Europe Ltd.

INDUSTRY

NCT02437591 - Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) | Biotech Hunter | Biotech Hunter